| Drug Name |
Cladribine |
| Drug ID |
BADD_D00479 |
| Description |
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. |
| Indications and Usage |
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01BB04; L04AA40 |
| DrugBank ID |
DB00242
|
| KEGG ID |
D01370
|
| MeSH ID |
D017338
|
| PubChem ID |
20279
|
| TTD Drug ID |
D05GJW
|
| NDC Product Code |
42658-010; 12502-5406; 0143-9871; 44087-4000; 54893-0115; 76055-0051; 63323-140; 59605-3006; 65129-1260; 76055-0052; 12502-4912; 58623-0037 |
| UNII |
47M74X9YT5
|
| Synonyms |
Cladribine | 2-Chlorodeoxyadenosine | 2-Chloro-2'-deoxyadenosine | 2'-Deoxy-2-chloroadenosine | Leustatin |
